Aldag Edward K JR

SEC source: 0001287865-20-000030 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,984,778

SEC source: 0001287865-20-000030 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,229,184

SEC source: 0001287865-20-000019 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,385,753

F2 · shares: Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's per share funds from operations, EBITDA, and acquisitions, as defined and set by our compensation committee, over the period from January 1, 2020 through December 31, 2022, with the opportunity to earn up to one third of the award for 2020 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of specific performance thresholds.

SEC source: 0001287865-20-000019 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,039,899

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2020.

SEC source: 0001287865-20-000008 · primary_doc.xml · derivative · entry 4

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,814

Underlying: Common stock, par value $0.001 · 106,073 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

F4 · derivative.exercise_date: The shares vested on January 1, 2020.

F4 · derivative.expiration_date: The shares vested on January 1, 2020.

SEC source: 0001287865-20-000008 · primary_doc.xml · nonDerivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,861,732

F3 · shares: Represents shares earned under the 2019 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on how the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. The shares vested on January 1, 2020.

SEC source: 0001287865-20-000008 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,472,316

F2 · shares: Represents additional shares earned under the 2018 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on how the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index.

SEC source: 0001287865-20-000008 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,313,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

SEC source: 0001287865-20-000001 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,207,130

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2020.

SEC source: 0001287865-19-000022 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,058,820

F1 · price: This transaction was executed in multiple trades at prices ranging from $19.58 to $19.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001287865-19-000015 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,160,784

SEC source: 0001287865-19-000006 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,434,361

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2019.

SEC source: 0001287865-19-000001 · primary_doc.xml · derivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,887

Underlying: Common stock, par value $0.001 · 100,331 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

F3 · derivative.exercise_date: The shares vested on January 1, 2019.

F3 · derivative.expiration_date: The shares vested on January 1, 2019.

SEC source: 0001287865-19-000001 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,316,129

F2 · shares: Represents additional shares earned based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on how the Company's relative total shareholder return compared to the SNL Healthcare REIT Index.

SEC source: 0001287865-19-000001 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,184,970

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

SEC source: 0001287865-18-000026 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,084,639

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2019.

SEC source: 0001287865-18-000023 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,873,541

SEC source: 0001287865-18-000008 · primary_doc.xml · derivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,218

Underlying: Common stock, par value $0.001 · 318,218 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award is the economic equivalent of one share of the Company's common stock.

F3 · shares: Represents the target number of shares that may be earned based on the achievement of specific performance thresholds pertaining to the Company's return on equity (40%), EBITDA (40%), and completed acquisitions (20%), as defined and set by our compensation committee, over the period from January 1, 2018 through December 31, 2020, with the opportunity to earn up to one third of the award in any one year for performance against the specified measures. However, more or less shares than the target number of shares may be earned based on our performance with the number of shares earned based on achievement of performance between points being interpolated on a linear basis. Furthermore, each of the performance based awards are subject to a modifier, which increases or decreases actual shares earned (both in one year and three years) based on the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. (continued on footnote 4)

F4 · shares: At the end of each of the performance periods, any earned shares during such period will vest on January 1 of the following calendar year. Dividends are paid on these shares only upon achievement of the performance measures.

F3 · derivative.exercise_date: Represents the target number of shares that may be earned based on the achievement of specific performance thresholds pertaining to the Company's return on equity (40%), EBITDA (40%), and completed acquisitions (20%), as defined and set by our compensation committee, over the period from January 1, 2018 through December 31, 2020, with the opportunity to earn up to one third of the award in any one year for performance against the specified measures. However, more or less shares than the target number of shares may be earned based on our performance with the number of shares earned based on achievement of performance between points being interpolated on a linear basis. Furthermore, each of the performance based awards are subject to a modifier, which increases or decreases actual shares earned (both in one year and three years) based on the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. (continued on footnote 4)

F4 · derivative.exercise_date: At the end of each of the performance periods, any earned shares during such period will vest on January 1 of the following calendar year. Dividends are paid on these shares only upon achievement of the performance measures.

F3 · derivative.expiration_date: Represents the target number of shares that may be earned based on the achievement of specific performance thresholds pertaining to the Company's return on equity (40%), EBITDA (40%), and completed acquisitions (20%), as defined and set by our compensation committee, over the period from January 1, 2018 through December 31, 2020, with the opportunity to earn up to one third of the award in any one year for performance against the specified measures. However, more or less shares than the target number of shares may be earned based on our performance with the number of shares earned based on achievement of performance between points being interpolated on a linear basis. Furthermore, each of the performance based awards are subject to a modifier, which increases or decreases actual shares earned (both in one year and three years) based on the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. (continued on footnote 4)

F4 · derivative.expiration_date: At the end of each of the performance periods, any earned shares during such period will vest on January 1 of the following calendar year. Dividends are paid on these shares only upon achievement of the performance measures.

SEC source: 0001287865-18-000008 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,916,606

F1 · shares: Shares vest at the beginning of each calendar quarter ending March 31, 2021; dividends are paid currently.

SEC source: 0001287865-18-000007 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,759,620

SEC source: 0001287865-18-000005 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,875,836

SEC source: 0001287865-18-000005 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,192,629

SEC source: 0001287865-18-000001 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,365,807

F1 · shares: Represents the additional number of shares that were earned on 2017 grants based on the achievement of specific performance thresholds as set by our compensation committee for the one-year performance period of 2017.

F2 · balance_after: The total amount of securities beneficially owned following the reported transaction includes a decrease of 159,331 shares as a result of forfeitures related to previously disclosed share awards.

SEC source: 0001287865-17-000016 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,372,197

F4 · shares: Shares may be earned based on the achievement of a multi-year cumulative total shareholder return as compared to pre-established returns set by our compensation committee. If the cumulative shareholder return from January 1, 2017 through December 31, 2019 is 27% or greater, then 30% of these shares will be earned ("2019 award"). If the cumulative shareholder return from January 1, 2017 through December 31, 2020 is 36% or greater, then 30% of these shares may be earned ("2020 award"). However, the maximum percentage cumulatively earned in connection with both the 2019 award and the 2020 award shall not exceed 30% of the total award. If the cumulative shareholder return from January 1, 2017 through December 31, 2021 is 45% or greater, then 100% of these shares will be earned less the shares earned with the 2019 award and the 2020 award. (continued on footnote 5)

F5 · shares: At the end of each of the performance periods, any earned shares during such period will vest on January 1 of the following calendar year. Dividends are paid on these shares only upon achievement of the performance measures.

SEC source: 0001287865-17-000016 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,887,309

F1 · shares: Represents the target number of shares that may be earned based on the achievement of specific performance thresholds as set by our compensation committee for the one-year performance period of 2017. However, more or less shares than the target number of shares may be earned based on our performance with the number of shares earned based on achievement of performance between points being interpolated on a linear basis. The pre-established performance thresholds for 2017 are as follows: a. Approximately 47% of the target shares may be earned based on the Company's return on equity ("ROE"), as defined by our compensation committee, over the period from January 1, 2017 through December 31, 2017. If the Company's ROE is equal to 12.5% for the one-year period, 50% of these shares will be earned. If the Company's ROE is equal to 13%, 100% of these shares will be earned. If the Company's ROE is greater than or equal to 13.5%, 200% of these shares will be earned. (continued on footnote 2)

F2 · shares: b. Approximately 42% of the target shares may be earned based on the achievement of a one-year total shareholder return as compared to the SNL U.S. REIT Healthcare Index ("Index") over the period from January 1, 2017 through December 31, 2017. If the shareholder return is equal to the Index minus 3% for the one-year period, 50% of these shares will be earned. If the shareholder return is equal to the Index, 100% of these shares will be earned. If the shareholder return is greater than or equal to the Index plus 3%, 200% of these shares will be earned. (continued on footnote 3)

F3 · shares: c. Approximately 11% of the target shares may be earned based on the Company's general and administrative expenses ("G&A") as a percentage of revenue, as defined by our compensation committee, over the period from January 1, 2017 through December 31, 2017. If the Company's G&A as a percentage of revenue is equal to 10% for the one-year period, 50% of these shares will be earned. If the Company's G&A as a percentage of revenue is equal to 9.5%, 100% of these shares will be earned. If the Company's G&A as a percentage of revenue is 9% or less, 200% of these shares will be earned. At the end of the one-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.

SEC source: 0001287865-17-000011 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,734,368

F1 · balance_after: The total amount of securities beneficially owned following the reported transaction includes a decrease of 250,000 shares as a result of forfeitures related to previously disclosed share awards.

SEC source: 0001287865-16-000039 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,286,213

F2 · shares: Up to 50% of the shares may be earned based on the achievement of a three-year cumulative total shareholder return as compared to pre-established multi-level returns set by our compensation committee. If the cumulative shareholder return is less than or equal to 27.0% for the three-year period, no shares will be earned, whereas if a total shareholder return of 35.0% or greater is achieved for the same period, then 100% of these shares will be earned. At the end of the three-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.

F3 · shares: The remaining 50% of the shares will be earned similar to that described above; however, the performance measure is against the MSCI US REIT Index (Index). If our total shareholder return over the three-year cumulative period is less than the Index minus 3%, then no shares will be earned, whereas if our total shareholder return is greater than the Index plus 3% for the same period, then 100% of these shares will be earned. At the end of the three-year performance period, any earned shares will be subject to an additional two years of ratable time-based vesting on an annual basis. Dividends are paid on these shares only upon achievement of the performance measures.

SEC source: 0001287865-16-000039 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,999,093

F1 · shares: Shares vest at the beginning of each calendar quarter ending March 31, 2019; dividends are paid currently.